Immunogenicity and safety of the new reduced-dose tetanus–diphtheria vaccine in healthy Korean adolescents: A comparative active control, double-blind, randomized, multicenter phase III study

• Main Authors: Seung Beom Han, Jung-Woo Rhim, Hye Jo Shin, Sang Yong Kim, Jong-Hyun Kim, Hyun-Hee Kim, Kyung-Yil Lee, Hwang Min Kim, Young Youn Choi, Sang Hyuk Ma, Chun Soo Kim, Dong Ho Kim, Dong Ho Ahn, Jin Han Kang
• Format: Article
• Language: English
• Published: Elsevier 2017-04-01
• Series: Journal of Microbiology, Immunology and Infection
• Subjects: diphtheria; diphtheria–tetanus vaccine; tetanus; Republic of Korea
• Online Access: http://www.sciencedirect.com/science/article/pii/S1684118215007549

A new reduced-dose tetanus–diphtheria (Td) vaccine was developed in Korea, and phase I and II clinical trials were successfully undertaken. We conducted this double-blind, randomized, multicenter phase III clinical trial to assess the immunogenicity and safety of the new Td vaccine. Methods: Healthy adolescents 11–12 years of age were enrolled and randomized to receive the new Td vaccine (study group) or a commercially available Td vaccine (control group). Blood samples were collected prior to and 4 weeks after the vaccination. Between the study and control groups, seroprotection rate, booster response, and geometric mean titer of antibodies against diphtheria and tetanus toxoids were compared after the vaccination. All solicited and unsolicited adverse events and serious adverse events during the 6-week study period were monitored. Results: A total of 164 adolescents received vaccination, and 156 of them were evaluated to assess immunogenicity. The seroprotection rate and geometric mean titer for antibodies against diphtheria were significantly higher in the study group, whereas those against tetanus were significantly higher in the control group. However, all seroprotection rates against diphtheria and tetanus in the study and control groups were high: 100% against diphtheria and tetanus in the study group, and 98.7% against diphtheria and 100% against tetanus in the control group. No significant differences in the frequency of solicited and unsolicited adverse events were observed between the two vaccine groups. Conclusion: The new Td vaccine is highly immunogenic and safe, and this new Td vaccine can be effectively used for preventing diphtheria and tetanus.